72 results about "TP53 Genes" patented technology

The invention provides a four-autoantibody combined detection kit for diagnosing an early esophageal squamous cancer and application thereof. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer comprises a solid substrate and antigen protein which coats the solid substrate; and the antigen protein comprises TP53, HRAS, CTAG1A and NSG1. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer, provided by the invention, has the advantages that the TP53, the HRAS, the CTAG1A and the NSG1 are firstly adopted as acombination to be used for early diagnosis of ESCC, higher sensibility and higher specificity are realized, the detection kit is conducive to further improvement of serologic screening quality of ESCC early diagnosis, and therefore, the cure rate and survival rate of patients are further promoted.

The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

The invention relates to the field of tumor gene, and discloses a high-flux sequencing detection method for tumor-targeted drugs related genes mutation, a group of primer pairs and a reagent thereof. The method is used for detecting mutation of tumor-targeted drugs related genes in an acceptor, the related genes comprise BRAF, EGFR, KRAS, NRAS, TP53, FGFR3, KIT, PIK3CA, RET, PTEN, and CTNNB1. The method comprises the following steps: extraction of sample DNA, target gene enrichment, primer sequence removal, joint connection, PCR amplification, library homogenization, library detection and high flux sequencing. The disclosed primer pairs enable multiple PCR enrichment and amplification on the tumor-targeted drugs related genes, the method can be used for detecting 115 mutation sites in the above 11 genes, a detection result can be a medication guidance for the tumor-targeted drugs, and provides a basis for exploitation of novel cancer drugs.

The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.

Methods are disclosed for genetically counseling a person based on one or more polymorphisms in his or her genes that sensitize him or her to toxic agents. Methods are also disclosed for genetically screening a group of individuals and/or a human population, based on, for example, ethnicity, race, religion or geographic region, to identify individuals with such polymorphisms for counseling. The methods can be used to counsel a person who has not been genetically tested for polymorphisms but who might have increased risk for sensitivity to toxic agents due to his or her membership in a particular group and/or population. The methods use correlations between genotypes of polymorphic alleles in a panel of cell lines and sensitivity of the cell lines to toxic agents. As examples, the methods are used to identify genotypes of allelic forms of the genes TP53, OGG1, ERCC2, XRCC1, and NOS3 that increase sensitivity or resistance of cells to toxic agents.

The invention belongs to the technical field of biology, and particularly relates to an MDCK (Madin-Darby canine kidney) cell line capable of stably expressing a human-derived TIGAR (TP53-induced glycolysis and apoptosis regulator) gene. The cell line is an MDCK cell line TG-418-E5 capable of stably expressing the human-derived TIGAR gene and contains a TIGAR coding gene sequence, and the preservation number of the cell line is CGMCC NO:12983. Through stable expression of the TIGAR gene in MDCK cells, anti-apoptosis capacity of the cells is improved, and the survival time of recombinant cells is prolonged. The method not only lays the foundation for research of application of MDCK serum-free fully-suspended culture in mass production of cell culture vaccines, but also increases breeding titer of avian influenza vaccine strains and saves the cost of a production process. Besides, the cell line TG-418-E5 has better application prospect in aspects of screening of anti-avian influenza virus drugs, screening of vaccine strains and production of the cell culture vaccines.

The invention relates to a primer group, reagent and/or kit and system for detecting lung cancer chemotherapy related genes, and application. The primer group contains primers for detecting gene mutation of ERCC1, MTHFR, GSTP1, XRCC1, DYNC2H1, ABCB1, CYP2C8*3, TP53, NQO1, CBR3, SOD2, CYP2C19, UGT1A1*6, TYMS, NT5C2 and CDA. The primer group, the reagent and/or the kit, the system and the application have the advantages of high accuracy, high specificity, high sensitivity, good precision and the like, and meanwhile, further have the advantages of sample saving, short detection period, easy operation, convenient analysis and the like.

The invention relates to the technical field of biology and the field of nucleic acid detection and relates to method for detecting multi-locus low-frequency mutation of free target DNA of lung cancerplasma and a kit. The invention provides high-sensitivity and high-flux method for detecting multi-locus mutation of free DNA of lung cancer plasma once and a kit. According to the detection method,a ddPCR technique and a next generation sequencing technique are combined for detecting the mutation of lung cancer crDNA. The detection method comprises the following steps: (1) preparing a digital PCR mixed liquid including a to-be-tested sample DNA template, a primer and a PCR premixing liquid; (2) preparing a digital PCR micro-reaction drop, and carrying out PCR amplified reaction; (3) recycling and purifying a PCR product; (4) preparing and amplifying PCR premixing liquid for the second time; (5) carrying out purification and library quality control on the PCR product; and (6) carrying out computer sequencing and data analysis. According to the detection method, hotspot mutation information of 10 genes including EGFR/BRAF/KRAS/PIK3A/MET2/ERBB2/AKT1/NRAS/TP53/PTEN of lung cancer can bedetected for one time, the cost can be remarkably lowered, and the high-sensitivity and high-flue detection of mutation information of lung cancer ctDNA can be realized.

The invention discloses a blood plasma specific fragment free DNA (deoxyribonucleic acid) quantitative detection kit comprising the following components: two primer pairs for amplifying TP53 gene fragments of which the lengths are respectively 400bp and 150bp, a primer pair for amplifying a reference gene Beta-actin, and fetal genome DNA, wherein the two primer pairs are consistent in backward primer sites, and the lengths of the amplified TP53 gene fragments are determined by virtue of a forward primer. According to the kit disclosed by the invention, a calibration system is introduced based on a fluorescent quantitative PCR (polymerase chain reaction) technology, the fetal genome DNA is used as background DNA, a house-keeping gene Beta-actin is used as the reference gene, a cancer suppressor gene TP53 is used as a target gene, an amplification primer is designed aiming at different lengths of fragments of the cancer suppressor gene TP53, different lengths of the fragments of the Beta-actin gene and the TP53 gene are synchronously amplified by adopting a real-time fluorescent quantitative PCR process, and the content of free DNA with specific fragment sizes in blood plasma can be quantitatively detected.

A probe combination for detecting cancer includes one or more sets of partial hepatitis B virus (HBV) targeting probes. When sequences of each of the sets of partial HBV targeting probes are aligned, an overall sequence of the aligned set of probes matches a reference sequence of a genome of a HBV genotype or a direct repeat (DR) region on the genome. In the aligned set of probes, each of the probes overlap with one or two adjacent probes by a portion of a length of the probe. The probe combination may further includes one or more sets of hotspot gene targeting probes targeting cancer hotspot genes such as CTNNB1, TERT, and TP53 genes, one or more sets of exogenous gene targeting probes targeting portions of a lambda phage genome, and endogenous gene targeting probes targeting endogenous genes such as GAPDH and GdX genes.

The present disclosure relates to a method of treating cancer using a composition comprising Nelfinavir, Metformin, Rosuvastatin, optionally along with a pharmaceutically acceptable excipient. The said composition is used for the treatment of cancer caused due to aberration in PTEN gene, optionally along with aberration in TP53 gene and related genes selected from group comprising PI3K, CDKN2A, MDM2 and MDM4.

Disclosed herein are multiplex methods for co-detecting a B cell marker, TP53 nucleic acid, and Chromosome 17 centromere DNA in a single sample. Samples stained for the B cell marker (e.g., CD79a protein), TP53 nucleic acid, and Chromosome 17 centromere DNA may allow for the identification of the subtype of chronic lymphocytic leukemia (CLL) with the 17p deletion. The methods feature staining the B cell marker (e.g., CD79a) a first distinct color, TP53 in a second distinct color, and chromosome 17 centromere DNA in a third distinct color. Further disclosed are nucleic acid probes specific for 19q12, INSR, ATM, DLEU2, TP53, and 13q12.

The invention discloses a kit for detecting gene mutation of diffuse large B-cell lymphoma and belongs to the field of gene detection and disease diagnosis. It is found that a certain connection exists between KCNG1 gene and diffuse large B cell lymphoma (DLBCL), and the kit can be used for auxiliary diagnosis of DLBCL by detecting whether G185A mutation exists in KCNG1 gene or not. The genes detected by the kit for detecting DLBCL gene mutation include a KCNG1 gene and MYD88, CD79B, EZH2, B2M, NOTCH2, STAT6 and TP53 genes which are determined to be related to DLBCL generation in the prior art. The invention provides a new material for auxiliary diagnosis of DLBCL; the kit can detect the mutation condition of the gene at one time, and provides a basis for early diagnosis, typing judgment,prognosis stratification and medication guidance of DLBCL.

The invention discloses a method for constructing a lung cancer multi-gene mutation library. The method can realize mutation of 1435 somatic cells of human genes EGFR, K-ras, B-raf, N-ras, PIK3CA, c-MET, TP53, c-Kit, PDGFRA, ALK, ROS1, RET, ERBB2, NTRK1 and NTRK3. The method can individually manage multiple target sequences and fast finish library construction. The whole library construction process is finished in 2-3h and the manual operation time is only 45min. The method can be used for Illumina and Ion torrent platforms. Through combination of the method and a high-throughput sequencing platform, the problem that a small amount of paraffin tissue slices and peripheral blood samples of a lung cancer patient need multi-gene and multi-target detection of somatic cells is solved and a costis low.